Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib and Rituximab in Marginal Zone Lymphoma
NCT07583810Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemtabrutinib in marginal zone lymphoma (MZL), sponsored by City of Hope. Primary endpoints: Incidence of unacceptable toxicity and Complete Response Rate up to 3 years. Started Oct 2026; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07583810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583810.